Navigation Links
Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
Date:11/1/2007

nces in 2008.

Poniard is continuing to evaluate picoplatin administered once every two weeks in the FOLPI regimen in its ongoing Phase 1 trial and has not yet reached the maximum tolerated dose for this dosing regimen.

About Picoplatin

Picoplatin has an improved safety profile compared to existing platinum- based chemotherapeutics and was designed to overcome platinum resistance. Poniard's strategy is to develop picoplatin as a platform product that can be used second-line in patients who are resistant or refractory to currently available platinums, such as small cell lung cancer (SCLC) patients, and first-line in patients, such as CRC patients, who cannot tolerate the toxicity profile of currently marketed platinums. We also plan to advance the use of picoplatin in new combination regimens in which platinums are not currently used, such as in the treatment of hormone-refractory prostate cancer (HRPC) patients, in order to improve efficacy. In addition to the Phase 2 trial in metastatic CRC, Poniard is evaluating intravenous picoplatin in an ongoing pivotal Phase 3 trial, known as SPEAR (Study of Picoplatin Efficacy After Relapse), in SCLC. This registrational trial is being conducted under a Special Protocol Assessment (SPA) from the U.S. Food and Drug Administration (FDA) and is evaluating overall survival as the primary endpoint.

The Company is also evaluating intravenous picoplatin in an ongoing Phase 2 trial in combination with docetaxel (Taxotere(R)) and prednisone in patients with metastatic HRPC. Oral picoplatin is being evaluated in a Phase 1 clinical trial in solid tumors.

Picoplatin has been tested in more than 600 patients in Phase 1 and 2 safety and efficacy studies.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead pla
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Poniard Pharmaceuticals Announces Promising Data From Interim Safety Analysis of Phase 1 Combination Trials of Picoplatin in Colorectal and Prostate Cancers
2. Poniard Pharmaceuticals Announces Clinical Data from Picoplatin Phase 2 Small Cell Lung Cancer Trial To Be Presented at American Society of Clinical Oncology Annual Meeting
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2008)... , CHICAGO, Dec. 1 ...d cerebral blood flow and a greater number of smal...s presented today at the annual meeting of the Rad..., The study, conducted at the University of No...to compare brain scans of older adults who exercis...
(Date:11/28/2008)...GÿRLITZ, Germany, November 28 Ger...l leadership in specialized HIV monitoring and,AI...d emerging countries. In,the year 2008, 2.5 milli...table, robust and highly affordable "CyFlow" syste...living with HIV/AIDS. Due to introduction of the,...
(Date:11/27/2008)...study finds the majority of acute lymphoblastic le...sent at the time of diagnosis , , MEMPHIS, ...ts at St. Jude Children,s Research Hospital have i...r cells of children with acute lymphoblastic leuke... pathway to designing treatments for ALL relapse i...
(Date:11/26/2008)...eased information density, automation and intellig... in ultrasound to an all new level , , CHIC...ens Healthcare ( www.siemens.com/healthcare ) ...olume Scanner (ABVS)(1), the world,s first multi-... the 94th Scientific Assembly and Annual Meeting o...
Breaking Medicine Technology:Exercise Helps Prevent Age-Related Brain Changes in Older Adults 2Exercise Helps Prevent Age-Related Brain Changes in Older Adults 3German Innovation for HIV/AIDS Diagnostics has Been Used 2.5 Million Times in 2008 2St. Jude Identifies Genomic Causes of a Certain Type of Leukemia Relapse 2St. Jude Identifies Genomic Causes of a Certain Type of Leukemia Relapse 3Siemens Introduces New Standard of Care for Breast Ultrasound 2Siemens Introduces New Standard of Care for Breast Ultrasound 3Siemens Introduces New Standard of Care for Breast Ultrasound 4Siemens Introduces New Standard of Care for Breast Ultrasound 5Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103 Vidaza 28R 29 Study in Myelodysplastic Syndromes and Acute Myelogeno 7980 1Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103 Vidaza 28R 29 Study in Myelodysplastic Syndromes and Acute Myelogeno 7980 2Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103 Vidaza 28R 29 Study in Myelodysplastic Syndromes and Acute Myelogeno 7980 3Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103 Vidaza 28R 29 Study in Myelodysplastic Syndromes and Acute Myelogeno 7980 4Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103 Vidaza 28R 29 Study in Myelodysplastic Syndromes and Acute Myelogeno 7980 5Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103 Vidaza 28R 29 Study in Myelodysplastic Syndromes and Acute Myelogeno 7980 6Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103 Vidaza 28R 29 Study in Myelodysplastic Syndromes and Acute Myelogeno 7980 7Jan Marini Skin Research Adds Two New Sheer Colors to Antioxidant Daily Face Protectant SPF 30 With PhytoMelanin 28TM 29 7977 1Jan Marini Skin Research Adds Two New Sheer Colors to Antioxidant Daily Face Protectant SPF 30 With PhytoMelanin 28TM 29 7977 2San Antonio Breast Cancer Symposium December 13th to 16th 2007 7974 1San Antonio Breast Cancer Symposium December 13th to 16th 2007 7974 2Gentler chemotherapy before stem cell transplant causes long term remission of follicular lymphoma 7971 1Gentler chemotherapy before stem cell transplant causes long term remission of follicular lymphoma 7971 2
...NESS WIRE)--May 17, 2007 - BioLineRx Ltd. (TASE:,B...nnounced today,that abstracts containing data from...s of BL-1020, first in class GABA-enhanced,antipsy...en,accepted for poster presentations at three lead...nted at the following,conferences:, -- Society of ...
...(BUSINESS WIRE)--May 18, 2007 - AVANT,Immunotherap...ve,preliminary results from an investigational dou...ating clinical trial of its,typhoid fever vaccine ...rchers found the single-dose, oral vaccine to be w...ccinated subjects,generating immune responses. Bas...
Other Medicine Technology:BioLineRx Presents Phase I Clinical Data of BL-1020 at Upcoming,Clinical Conferences 2BioLineRx Presents Phase I Clinical Data of BL-1020 at Upcoming,Clinical Conferences 3Avant's Typhoid Fever Vaccine Demonstrates Excellent Clinical,Potential 2Avant's Typhoid Fever Vaccine Demonstrates Excellent Clinical,Potential 3Avant's Typhoid Fever Vaccine Demonstrates Excellent Clinical,Potential 4Avant's Typhoid Fever Vaccine Demonstrates Excellent Clinical,Potential 5
(Date:12/1/2008)...gene repressors for anticancer therapy , Miche...ring Cancer Center, New York, have developed a new...therapeutic purposes, and used this to mediate eff...oding RNA molecules known as miRNAs are powerful n..., the miRNA miR-181a was harnessed to segregate ex...
(Date:12/1/2008)...ntrepreneur, television and,radio host Ryan Seacr...hn,Bendheim will be honored by the Cedars-Sinai B..." Gala, December 2, 2008, at the Hyatt Regency Cen...oard of Governors, co-chairs the,event with Debbe...The "Road To,A Cure" Gala is sponsored by Lexus, ...
(Date:12/1/2008)...-- Democratic National Committee Chairman Howard D...ting World AIDS Day on its 20th Anniversary: , ...20080519/DNCLOGO ) , , "It,s been 20 years ...made strides, much work remains to be done to tack...trategy. We must focus not only on preventing the...
(Date:12/1/2008)... -- Americans United for Life (AUL) today announc...tion opposing the federal "Freedom of Choice Act" ... resolution immediately when they convene their 20...resident & CEO said, "The so-called ,Freedom o...ts and promotes the abortion industry, sacrifices ...
Breaking Medicine News(10 mins):Health News:JCI online early table of contents: Dec. 1, 2008 2Health News:JCI online early table of contents: Dec. 1, 2008 3Health News:JCI online early table of contents: Dec. 1, 2008 4Health News:Cedars-Sinai Board of Governors to Honor Ryan Seacrest & John Bendheim at Annual 'Road To A Cure' Gala 2Health News:Americans United for Life Urges State Legislatures to Oppose Federal Power Grab: Provides Model Resolution Denouncing Freedom of Choice Act (FOCA) 2
...the brain areas preoperative brain could effective...at is to appear in the September issue of Radiolog...// and language areas of the brain with functional...uld help the surgeons in pinpointing the brain tum...
...in almost every medicine cabinet, may help in easi...innesota's Mayo Clinic.// Aspirin is known to hel...art attacks, strokes and several types of cancer a...ay that now it may help solve some of the urinary ...
... was described as being one of the crown jewels in...mmersmith Hospitals NHS Trust acquired the// hospi...d predicted that the hospital had a great future i...which had six theatres and 105 beds, was revamped ...
...s suspected of having the human variety of mad cow...nd was admitted to a Hog Kong hospital// after he ...ong said the man came to the country on April 4 an... The man is of Chinese origin and underwent intes...
Other Medicine News:Health News:fMRI Prior to surgery Could Help In Outcome Of Tumor Surgery 2Health News:fMRI Prior to surgery Could Help In Outcome Of Tumor Surgery 3
... aspherical optics. Includes XHL halogen bulb. The...y means of the aspherical optical system avoids co...Beta 200 allows you to view the whole of the illum...il. Conventional ophthalmoscopes often let you see...
The Panoptic ophthalmoscope incorporates an innovative and patented new optical design called axial Pointsource optics. This enabling technology makes it easier to enter small pupils and provides a d
Woodlyn Refractor offers the option to either rotate the better-one better-two refinement knob, or rotate the low sphere disc.
The Ultramatic Rx Master is designed and constructed to provide years of reliable service and give the professional distinctive features that measurably improve procedures. It embodies the characteri
Medicine Products: